<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83116">
  <stage>Registered</stage>
  <submitdate>29/08/2008</submitdate>
  <approvaldate>16/09/2008</approvaldate>
  <actrnumber>ACTRN12608000461392</actrnumber>
  <trial_identification>
    <studytitle>Clinical Trial of a Selective Estrogen Receptor Modulator (raloxifene) in Schizophrenia</studytitle>
    <scientifictitle>Clinical Trial of a Selective Estrogen Receptor Modulator (raloxifene) in the treatment of cognitive deficits and psychotic symptoms of patients with schizophrenia</scientifictitle>
    <utrn />
    <trialacronym>CASSI study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>cognitive deficits in patients with schizophrenia</healthcondition>
    <healthcondition>psychotic symptoms in patients with schizophrenia</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Schizophrenia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>raloxifene at a daily oral intake dose of 120 mg/day. A thirteen week double-blind, cross-over design will be used in which patients will receive either raloxifene or placebo as an adjunctive treatment to their previously stabilized antipsychotic medication. Following treatment in the first 6-week phase, patients will then enter a one week wash-out before entering the second 6-week phase consisting of the alternate treatment (raloxifene or placebo). Thus, in total, participants will be treated with raloxifene for a period of 6 weeks.</interventions>
    <comparator>placebo (lactose) pill administered orally.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Verbal Fluency Controlled Oral Word Association Test</outcome>
      <timepoint>baseline, week 6, week 13</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>verbal immediate and delayed story recall Wechlser Memory Scale III</outcome>
      <timepoint>baseline, week 6, week 13</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>working memory Letter-Number Sequencing Wechsler Adult Intelligence Scale III</outcome>
      <timepoint>baseline, week 6, week 13</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>positive and negative symptoms assessed using Positive and Negative Symptom Scale (PANSS) scores</outcome>
      <timepoint>baseline, week 6, week 13</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male and female patients with schizophrenia between the ages of 18 and 45 who have been receiving any antipsychotic medication for at least one year can participate.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Any patients with a psychiatric diagnosis other than schizophrenia or a history of substance dependence (within past 5 years), head injuries with loss of consciousness, seizures, central nervous system infection, diabetes, hypertension, lactose intolerance, superficial thrombophlebitis (pain and inflammation in a vein just under the skin), thromboembolic disease (blood clotting disease), congestive heart failure, or who have had reactions to raloxifene will be excluded.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants were enrolled and allocated a participant number obtained from Prince of Wales Hospital Pharmacy which controlled the randomization schedule. </concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software (i.e., computerised sequence generation).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>ANOVA, t-tests, cluster analyses. The number of participants was determined on the basis of a power analysis.  The number of participants would be large enough to detect an effect of treatment alone, however, the larger sample size was required to detect an effect of treatment on the basis of ESR1 genotype and diagnosis which would reduce the numbers in each of the groups. </statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>22/09/2008</anticipatedstartdate>
    <actualstartdate>22/07/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/06/2012</actualenddate>
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA</recruitmentstate>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <postcode>2031</postcode>
    <postcode>2035</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of New South Wales</primarysponsorname>
    <primarysponsoraddress>Sydney, NSW 2052</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of New South Wales</fundingname>
      <fundingaddress>Barker Street
Randwick NSW 2031</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Schizophrenia Research Institute</fundingname>
      <fundingaddress>384 Victoria Street
Darlinghurst NSW 2010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>16 Marcus Clarke Street
Canberra, ACT2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>New South Wales Ministry of Health</fundingname>
      <fundingaddress>Locked Mail Bag 961
North Sydney, NSW 2059</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of New South Wales</sponsorname>
      <sponsoraddress>Barker Street
Randwick NSW 2031</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Prince of Wales Medical Research Institute</sponsorname>
      <sponsoraddress>Barker and Easy Streets
Randwick NSW 2031</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objectives of this study are to determine the extent to which 1) a hormone intervention therapy will reduce psychotic symptoms and improve cognitive function in patients with schizophrenia, 2) genetic changes in the oestrogen receptor alpha gene can be used to predict cognitive improvement in patients with schizophrenia, and 3) hormone intervention therapy will modify brain activation as assessed by functional Magnetic Resonance Imaging in patients with schizophrenia. Our hypotheses are: 1) adjunctive administration of a selective estrogen receptor modulator (SERM) will improve clinical symptoms and estrogen-sensitive cognitive deficits exhibited by patients with schizophrenia, 2) common variation in the oestrogen receptor alpha gene will predict the degree of cognitive improvement with SERM treatment in patients with schizophrenia, 3) adjunctive SERM treatment will modify dysfunctional brain activity during a cognitive test in patients with schizophrenia, and 4) that the altered SERM related dorsolateral prefrontal activity will be related to specific oestrogen receptor alpha genotypes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of New South Wales Human Research Ethics Committee [HREC]</ethicname>
      <ethicaddress>Barker Street
Randwick NSW 2031</ethicaddress>
      <ethicapprovaldate>9/08/2007</ethicapprovaldate>
      <hrec>UNSW HREC 07121</hrec>
      <ethicsubmitdate>10/05/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>South East Sydney Illawarra Area Health Service Human Research Ethics Committee [HREC]</ethicname>
      <ethicaddress>Avoca Street
Randwick NSW 2031</ethicaddress>
      <ethicapprovaldate>23/07/2008</ethicapprovaldate>
      <hrec>SESIAHS HREC 07/259</hrec>
      <ethicsubmitdate>30/10/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Adelaide Health Service</ethicname>
      <ethicaddress>11 Hindmarsh Square, Adelaide, SA 5000</ethicaddress>
      <ethicapprovaldate>15/09/2011</ethicapprovaldate>
      <hrec>2010188</hrec>
      <ethicsubmitdate>7/07/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Thomas Weickert</name>
      <address>Neuroscience Research Australia
Barker Street
Randwick, NSW 2031</address>
      <phone>02 9399 1730</phone>
      <fax>02 9399 1034</fax>
      <email>t.weickert@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Thomas Weickert</name>
      <address>Neuroscience Research Australia
Barker Street
Randwick, NSW 2031</address>
      <phone>02 9399 1730</phone>
      <fax>02 9399 1034</fax>
      <email>t.weickert@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Thomas Weickert</name>
      <address>Neuroscience Research Australia
Barker Street
Randwick, NSW 2031</address>
      <phone>02 9399 1730</phone>
      <fax>02 9399 1034</fax>
      <email>t.weickert@unsw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Thomas Weickert</name>
      <address>Neuroscience Research Australia
Barker Street
Randwick, NSW 2031</address>
      <phone>02 9399 1730</phone>
      <fax>02 9399 1034</fax>
      <email>t.weickert@unsw.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>